New study highlights enabling factors for biopharmaceutical innovation in middle-income countries
- Commissioned by IFPMA, the study identifies tailored, consistent long-term government policies as key factors to foster biopharmaceutical innovation
An independent study on biopharmaceutical innovation in middle-income countries was released today at the 26 th IFPMA Assembly in Geneva. The report analyzed key national political and economic factors that foster biopharmaceutical innovation.
The study, Policies that encourage innovation in middle-income countries, was conducted by Charles River Associates (CRA), an independent global consulting firm, and examined growing biopharmaceutical innovation sectors in Brazil, China, Colombia, India, Malaysia, Russia, South Africa and South Korea.
“In recent years, the number of countries where biopharmaceutical innovation takes places has increased, and this trend is expected to continue,” said Eduardo Pisani, IFPMA Director General. “Middle-income countries are becoming increasingly important for innovative activities ranging from early stage research to clinical development. We commissioned this report, because it is crucial for governments and industry to have a clearer understanding of what stimulates and drives innovation in these countries.”
The report highlighted the primary success factor as consistent long-term policy and legal frameworks. These should be coupled with effective coordination of national industrial and health policies, encouragement of collaborations between stakeholders, and adequate intellectual property protection. The report further suggests that some countries specialize in those stages of the innovation process in which they have a competitive advantage.
According to Tim Wilsdon, CRA Vice President, “Learning from the recent experience of a diverse set of middle-income countries, our report documents how targeted, co-ordinated and consistent government policies, tailored to a country’s capabilities, are key components for success. Other enabling factors include strong research institutions and medical schools and an environment that encourages partnership between the different stakeholders.”
Further information about CRA’s findings can be found at CRA Full Report and CRA Key Findings.
Geneva, 31 October 2012
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.Learn more
Media ContactElliot Dunster email@example.com